Mechanisms of obesity and related pathology: Linking immune responses to metabolic stress

FEBS Journal

Volumn 276, Issue 20, 2009, Pages 5747-5754

  Karalis, Katia P ^a,b   Giannogonas, Panagiotis ^a   Kodela, Elisavet ^a   Koutmani, Yassemi ^a   Zoumakis, Manolis ^c   Teli, Thalia ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

11 HSD; Adipokines; Endoplasmic reticulum; Glucocorticoid; IKK NF B; Inflammation; JNK; Neuropeptides; Obesity; Oxidative stress

Indexed keywords

I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ADIPOSE TISSUE; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INSULIN RESISTANCE; METABOLIC STRESS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SHORT SURVEY;

ANIMALS; ENDOPLASMIC RETICULUM; HUMANS; I-KAPPA B KINASE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; OBESITY; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 70349484669     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2009.07304.x     Document Type: Short Survey

References (91)

1. Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ Ezzati M (2009) The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med 6, e1000058, doi :.
2. Misra A Khurana L (2008) Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 93, S9 S30.
3. Jackson RS, Creemers JW, Ohagi S, Raffin-Sanson ML, Sanders L, Montague CT, Hutton JC O'Rahilly S (1997) Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 16, 303 306.
4. Krude H, Biebermann H, Luck W, Horn R, Brabant G Gruters A (1998) Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19, 155 157.
5. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA et al. (1997) Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387, 903 908.
6. Vaisse C, Clement K, Guy-Grand B Froguel P (1998) A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet 20, 113 114.
7. Bell CG, Walley AJ Froguel P (2005) The genetics of human obesity. Nat Rev Genet 6, 221 234.
8. Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, Walts B, Perusse L Bouchard C (2006) The human obesity gene map: the 2005 update. Obesity (Silver Spring) 14, 529 644.
9. Walley AJ, Asher JE Froguel P (2009) The genetic contribution to non-syndromic human obesity. Nat Rev Genet 10, 431 442.
10. Chandra RK (1981) Immune response in overnutrition. Cancer Res 41, 3795 3796.
11. Ebstein W (1876) Zur therapie des Diabetes mellitus, insbesondere uber die Anwendung des salicylsauren Natron bei demselben. Berliner Klinische Wochenschrift 13, 337 340.
12. Reid EW (1901) Transport of fluid by certain epithelia. J Physiol 26, 436 444.
13. Shoelson S (2002) Invited comment on W. Ebstein: on the therapy of diabetes mellitus, in particular on the application of sodium salicylate. J Mol Med 80, 618 619.
14. Nieman DC, Nehlsen-Cannarella SI, Henson DA, Butterworth DE, Fagoaga OR, Warren BJ Rainwater MK (1996) Immune response to obesity and moderate weight loss. Int J Obes Relat Metab Disord 20, 353 360.
15. Womack J, Tien PC, Feldman J, Shin JH, Fennie K, Anastos K, Cohen MH, Bacon MC Minkoff H (2007) Obesity and immune cell counts in women. Metabolism 56, 998 1004.
16. Shoelson SE, Lee J Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116, 1793 1801.
17. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M Shoelson SE (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293, 1673 1677.
18. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444, 860 867.
19. Wellen KE Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin Invest 115, 1111 1119.
20. Purnell JQ, Kahn SE, Samuels MH, Brandon D, Loriaux DL Brunzell JD (2009) Enhanced cortisol production rates, free cortisol, and 11beta-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss. Am J Physiol Endocrinol Metab 296, E351 E357.
21. Seckl JR Walker BR (2001) Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action. Endocrinology 142, 1371 1376.
22. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR et al. (1997) 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 94, 14924 14929.
23. Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ Seckl JR (2001) Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 276, 41293 41300.
24. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR Flier JS (2001) A transgenic model of visceral obesity and the metabolic syndrome. Science 294, 2166 2170.
25. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Heintze U, Janke J, Luft FC Sharma AM (2004) Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes Res 12, 9 17.
26. Valsamakis G, Anwar A, Tomlinson JW, Shackleton CH, McTernan PG, Chetty R, Wood PJ, Banerjee AK, Holder G, Barnett AH et al. (2004) 11beta- hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab 89, 4755 4761.
27. Schnackenberg CG (2008) 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome. Curr Opin Investig Drugs 9, 295 300.
28. Chrousos GP Gold PW (1992) The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 267, 1244 1252.
29. Feinstein R, Kanety H, Papa MZ, Lunenfeld B Karasik A (1993) Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 268, 26055 26058.
30. Hotamisligil GS, Shargill NS Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 87 91.
31. Hotamisligil GS Spiegelman BM (1994) Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 43, 1271 1278.
32. Uysal KT, Wiesbrock SM, Marino MW Hotamisligil GS (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389, 610 614.
33. Rotter V, Nagaev I Smith U (2003) Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278, 45777 45784.
34. Sartipy P Loskutoff DJ (2003) Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 100, 7265 7270.
35. Fried SK, Bunkin DA Greenberg AS (1998) Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83, 847 850.
36. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K et al. (1996) Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 2, 800 803.
37. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL Ferrante AW Jr. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112, 1796 1808.
38. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112, 1821 1830.
39. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL Ferrante AW Jr. (2006) CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116, 115 124.
40. Lumeng CN, DelProposto JB, Westcott DJ Saltiel AR (2008) Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 57, 3239 3246.
41. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, Red Eagle A, Vats D, Brombacher F, Ferrante AW et al. (2007) Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447, 1116 1120.
42. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3, 23 35.
43. Charriere G, Cousin B, Arnaud E, Andre M, Bacou F, Penicaud L Casteilla L (2003) Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem 278, 9850 9855.
44. Chung S, Lapoint K, Martinez K, Kennedy A, Boysen Sandberg M McIntosh MK (2006) Preadipocytes mediate lipopolysaccharide-induced inflammation and insulin resistance in primary cultures of newly differentiated human adipocytes. Endocrinology 147, 5340 5351.
45. Khazen W, M'Bika JP, Tomkiewicz C, Benelli C, Chany C, Achour A Forest C (2005) Expression of macrophage-selective markers in human and rodent adipocytes. FEBS Lett 579, 5631 5634.
46. Kolonin MG, Saha PK, Chan L, Pasqualini R Arap W (2004) Reversal of obesity by targeted ablation of adipose tissue. Nat Med 10, 625 632.
47. Ghanim H, Mohanty P, Deopurkar R, Sia CL, Korzeniewski K, Abuaysheh S, Chaudhuri A Dandona P (2008) Acute modulation of toll-like receptors by insulin. Diabetes Care 31, 1827 1831.
48. Vitseva OI, Tanriverdi K, Tchkonia TT, Kirkland JL, McDonnell ME, Apovian CM, Freedman J Gokce N (2008) Inducible Toll-like receptor and NF-kappaB regulatory pathway expression in human adipose tissue. Obesity (Silver Spring) 16, 932 937.
49. Song MJ, Kim KH, Yoon JM Kim JB (2006) Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 346, 739 745.
50. Davis JE, Gabler NK, Walker-Daniels J Spurlock ME (2008) Tlr-4 deficiency selectively protects against obesity induced by diets high in saturated fat. Obesity (Silver Spring) 16, 1248 1255.
51. Suganami T, Mieda T, Itoh M, Shimoda Y, Kamei Y Ogawa Y (2007) Attenuation of obesity-induced adipose tissue inflammation in C3H/HeJ mice carrying a Toll-like receptor 4 mutation. Biochem Biophys Res Commun 354, 45 49.
52. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, Schenka AA, Araujo EP, Vassallo J, Curi R, Velloso LA et al. (2007) Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 56, 1986 1998.
53. Abe M, Matsuda M, Kobayashi H, Miyata Y, Nakayama Y, Komuro R, Fukuhara A Shimomura I (2008) Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages. Arterioscler Thromb Vasc Biol 28, 871 877.
54. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425 432.
55. Fantuzzi G (2006) Leptin: nourishment for the immune system. Eur J Immunol 36, 3101 3104.
56. La Cava A Matarese G (2004) The weight of leptin in immunity. Nat Rev Immunol 4, 371 379.
57. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H et al. (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307, 426 430. (Pubitemid 40139988)
58. Scherer PE, Williams S, Fogliano M, Baldini G Lodish HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270, 26746 26749.
59. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409, 307 312.
60. Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J Saavedra JM (2006) Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 552, 112 122.
61. Kos K, Harte AL, James S, Snead DR, O'Hare JP, McTernan PG Kumar S (2007) Secretion of neuropeptide Y in human adipose tissue and its role in maintenance of adipose tissue mass. Am J Physiol Endocrinol Metab 293, E1335 E1340.
62. Yang K, Guan H, Arany E, Hill DJ Cao X (2008) Neuropeptide Y is produced in visceral adipose tissue and promotes proliferation of adipocyte precursor cells via the Y1 receptor. FASEB J 22, 2452 2464.
63. Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, Johnson MD, Lee EW, Burnett MS, Fricke ST, Kvetnansky R et al. (2007) Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 13, 803 811.
64. Digby JE, Chen J, Tang JY, Lehnert H, Matthews RN Randeva HS (2006) Orexin receptor expression in human adipose tissue: effects of orexin-A and orexin-B. J Endocrinol 191, 129 136.
65. Karagiannides I Pothoulakis C (2007) Obesity, innate immunity and gut inflammation. Curr Opin Gastroenterol 23, 661 666.
66. Vale W, Spiess J, Rivier C Rivier J (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213, 1394 1397.
67. Gay J, Kokkotou E, O'Brien M, Pothoulakis C Karalis KP (2006) Interleukin-6 genetic ablation protects from trinitrobenzene sulfonic acid-induced colitis in mice. Putative effect of antiinflammatory cytokines. Neuroimmunomodulation 13, 114 121.
68. Friedberg M, Zoumakis E, Hiroi N, Bader T, Chrousos GP Hochberg Z (2003) Modulation of 11 beta-hydroxysteroid dehydrogenase type 1 in mature human subcutaneous adipocytes by hypothalamic messengers. J Clin Endocrinol Metab 88, 385 393.
69. Seres J, Bornstein SR, Seres P, Willenberg HS, Schulte KM, Scherbaum WA Ehrhart-Bornstein M (2004) Corticotropin-releasing hormone system in human adipose tissue. J Clin Endocrinol Metab 89, 965 970.
70. Zouboulis CC, Seltmann H, Hiroi N, Chen W, Young M, Oeff M, Scherbaum WA, Orfanos CE, McCann SM Bornstein SR (2002) Corticotropin-releasing hormone: an autocrine hormone that promotes lipogenesis in human sebocytes. Proc Natl Acad Sci USA 99, 7148 7153.
71. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271, 665 668.
72. Aguirre A, Lopez T, Lopez-Bayghen E Ortega A (2000) Glutamate regulates kainate-binding protein expression in cultured chick Bergmann glia through an activator protein-1 binding site. J Biol Chem 275, 39246 39253.
73. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M Hotamisligil GS (2002) A central role for JNK in obesity and insulin resistance. Nature 420, 333 336.
74. Kaneto H, Nakatani Y, Miyatsuka T, Kawamori D, Matsuoka TA, Matsuhisa M, Kajimoto Y, Ichijo H, Yamasaki Y Hori M (2004) Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 10, 1128 1132.
75. Vallerie SN, Furuhashi M, Fucho R Hotamisligil GS (2008) A predominant role for parenchymal c-Jun amino terminal kinase (JNK) in the regulation of systemic insulin sensitivity. PLoS ONE 3, e3151.
76. Hotamisligil GS Erbay E (2008) Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 8, 923 934.
77. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J Karin M (2005) IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11, 191 198.
78. Solinas G, Vilcu C, Neels JG, Bandyopadhyay GK, Luo JL, Naugler W, Grivennikov S, Wynshaw-Boris A, Scadeng M, Olefsky JM et al. (2007) JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab 6, 386 397.
79. Makowski L, Brittingham KC, Reynolds JM, Suttles J Hotamisligil GS (2005) The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem 280, 12888 12895.
80. Tuncman G, Erbay E, Hom X, De Vivo I, Campos H, Rimm EB Hotamisligil GS (2006) A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci USA 103, 6970 6975.
81. Houstis N, Rosen ED Lander ES (2006) Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440, 944 948.
82. Scheuner D, Song B, McEwen E, Liu C, Laybutt R, Gillespie P, Saunders T, Bonner-Weir S Kaufman RJ (2001) Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol Cell 7, 1165 1176.
83. Ron D Walter P (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8, 519 529.
84. Urano F, Wang X, Bertolotti A, Zhang Y, Chung P, Harding HP Ron D (2000) Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287, 664 666.
85. Ozawa K, Miyazaki M, Matsuhisa M, Takano K, Nakatani Y, Hatazaki M, Tamatani T, Yamagata K, Miyagawa J, Kitao Y et al. (2005) The endoplasmic reticulum chaperone improves insulin resistance in type 2 diabetes. Diabetes 54, 657 663. (Pubitemid 40322067)
86. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Gorgun CZ Hotamisligil GS (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137 1140.
87. Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, Myers MG Jr. Ozcan U (2009) Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab 9, 35 51.
88. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T Donath MY (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356, 1517 1526.
89. Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J Shoelson SE (2008) Use of Salsalate to Target Inflammation in the Treatment of Insulin Resistance and Type 2 Diabetes. Clin Transl Sci 1, 36 43.
90. Chen Y, Zhu J, Lum PY, Yang X, Pinto S, MacNeil DJ, Zhang C, Lamb J, Edwards S, Sieberts SK et al. (2008) Variations in DNA elucidate molecular networks that cause disease. Nature 452, 429 435.
91. Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, Zhu J, Carlson S, Helgason A, Walters GB, Gunnarsdottir S et al. (2008) Genetics of gene expression and its effect on disease. Nature 452, 423 428.